| Autor: |
Gordon JK; Department of Rheumatology, Hospital for Special Surgery, New York, NY 10021, USA., Showalter K; Department of Rheumatology, Hospital for Special Surgery, New York, NY 10021, USA., Wu Y; Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.; Department of Psychiatry, McGill University, Montreal, QC, Canada., Kwakkenbos L; Department of Clinical Psychology, Radboud University, Nijmegen, Netherlands., Carrier ME; Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada., Henry RS; Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.; Department of Psychiatry, McGill University, Montreal, QC, Canada., Østbø N; Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada., Nordlund J; Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada., Bourgeault A; Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada., Cañedo-Ayala M; Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada., Carboni-Jiménez A; Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada., Denton CP; Centre for Rheumatology and Connective Tissue Diseases, Division of Medicine, University College London, London, UK., Mouthon L; Service de Médecine Interne, Centre de Référence Maladies Autoimmunes et Systémiques Rares d'Ile de France, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France.; APHP-CUP, Hôpital Cochin, Université de Paris, Paris, France., Thombs BD; Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.; Department of Psychiatry, McGill University, Montreal, QC, Canada.; Department of Medicine, McGill University, Montreal, QC, Canada.; Department of Psychology, McGill University, Montreal, QC, Canada.; Department of Educational and Counselling Psychology, McGill University, Montreal, QC, Canada.; Biomedical Ethics Unit, McGill University, Montreal, QC, Canada., Spiera RF; Department of Rheumatology, Hospital for Special Surgery, New York, NY 10021, USA. |
| Abstrakt: |
Competing Interests: Funding for this study was provided by the Canadian Institutes of Health Research (CIHR; GA4-177764). Additionally, the Scleroderma Patient-centered Intervention Network (SPIN) has received funding for the SPIN Cohort and to support studies, including the present study, from the Arthritis Society; the Lady Davis Institute for Medical Research of the Jewish General Hospital, Montreal, Canada; the Jewish General Hospital Foundation, Montreal, Canada; McGill University, Montreal, Canada; the Scleroderma Society of Ontario; Scleroderma Canada; Sclérodermie Québec; Scleroderma Manitoba; Scleroderma Atlantic; the Scleroderma Association of BC; Scleroderma SASK; Scleroderma Australia; Scleroderma New South Wales; Scleroderma Victoria; and Scleroderma Queensland. YW was supported by a Fonds de recherche du Québec—Santé Postdoctoral Training Fellowship, RSH was supported by a CIHR Postdoctoral Training Award, and BDT was supported by a Tier 1 Canada Research Chair, all outside of the present work. No sponsor or funder was involved in the study design; in the collection, analysis, and interpretation of the data; in the writing of the report; or in the decision to submit the paper for publication. JKG, KS, LK, M-EC, RSH, CPD, LM, BDT, RFS, and members of the SPIN SARS-CoV-2 Vaccination Patient Advisory Team contributed to the conception and design of study. M-EC, RSH, NØ, JN, AB, MC-A, AC-J, and BDT contributed to oversight and management of data collection. YW and BDT contributed to data analysis and accessed and verified the underlying data. All authors contributed to the interpretation of results. JKG and KS drafted the manuscript. All authors provided a critical review and approved the final manuscript. JKG is the guarantor. A full list of the SPIN investigators is listed in the appendix. JKG and KS are joint first authors; BDT and RFS are joint senior authors. JKG reports grants from Cumberland and Eicos, outside of the submitted work. CPD reports personal fees from Janssen, GlaxoSmithKline (GSK), Bayer, Sanofi-Aventis, Galapagos, Boehringer Ingelheim, Roche, CSL Behring, Corbus Pharmaceuticals, Acceleron Pharma, Horizon Therapeutics, and ARXX Therapeutics, all outside the submitted work. LM reports personal fees from Actelion/Johnson & Johnson, grants from LFB, non-financial support from Octapharma, and non-financial support from Grifols, all outside of the submitted work. RFS reports grants from Roche-Genentech, GSK, Boehringer Ingelheim, Chemocentryx, Corbus Pharmaceuticals, Formation Biologics, InflaRx, Kadmon, AstraZeneca, and Principia Biopharma, and consulting fees from AbbVie, Roche-Genentech, GSK, Sanofi, Janssen, Chemocentryx, Formation Biologics, and Chemomab Therapeutics, all outside the submitted work. All other authors declare no competing interests. De-identified individual participant data will be made available 12 months after publication upon request to the corresponding author and presentation of a methodologically sound proposal that is approved by the SPIN Data Access and Publications Committee. |
